Enclosed is the transcript of the conference call held on 01.08.2026.

AI summary - Q1 FY27 consolidated revenue grew 10% y-y to INR 264 Cr; standalone revenue down 6% y-y but up 5% q-o-q to INR 203 Cr - EBITDA margin at 37% consolidated, 43% standalone; PAT margin 28% consolidated, 36% standalone - HALS sales now 22% of consolidated revenue, with exports contributing nearly 50% of HALS sales - Strategic collaboration with Swiss partner Geneus Chem for advanced HALS technology; expected INR 300-350 Cr incremental revenue over 3-4 years - Hydroquinone and catechol plant stabilized; commercial supplies ramping from Q2 FY27 - Performance Chemical 2 plant expected commercial start in Q3 FY27 (Nov-Dec 2026) - Supply chain disruptions impacted volumes in Q1; improvements expected in Q2 but raw material price volatility remains - Long-term contract with Kemin for key ingredients with 5-year supply commitment; capacity expansion underway - EBITDA margins expected to improve with higher grade HALS sales and operational efficiencies - Export approvals and commercial shipments for HALS ramping up, supporting growth and margin expansion